One million anti-Covid-19 vaccine doses from Cuba to Nicaragua

'It is the first vaccine against Covid-19 developed in Latin America, by the CIGB. The transport service was offered by EMCOMED and the export service, by Farmacuba', the message underlines.

At the beginning of this month, the Sanitary Regulation Authority of the Nicaraguan Ministry of Health granted the Emergency Use Validation Certificate to Cuban Soberana 02 and Abdala vaccines.

'The Health Regulation Authority of the Nicaraguan Ministry of Health (MINSA) grants the Emergency Use Validation Certificate to Cuban vaccines Soberana and Abdala', a message from company BioCubaFarma underlined on Twitter.

'This authorization is made in accordance with the quality, safety and efficacy requirements established by the Nicaraguan Technical Standards', it continues.

'The certificate granted by the Nicaraguan Regulatory Authority indicates that the Soberana and Abdala vaccines are offered as a therapeutic tool with safe access to reduce the contagiousness of Covid-19, caused by the SARS-Cov-2 virus', the Cuban entity expressed.

Cuba has three anti-Covid-19 plans that exceed the ground standard imposed by the World Health Organization (50 percent) to be declared vaccines and one of these, 'Abdala', has already received authorization for emergency use in the country, as well as 'Soberana 02' for the pediatric population.

'Abdala', designed by the Center for Genetic Engineering and Biotechnology (CIGB), first vaccine in Latin America, showed 92.28 percent efficacy in its three-shot plan.

The Finlay Institute of Vaccines (IFV) Soberana 02 vaccine is added, which, with two injections, showed 65.6 percent in its final efficacy evaluation on symptomatic disease, a figure that increased after the 62 percent reported in the intermediate study.

The IFV also announced the efficacy of 91.2 percent of the two-dose plan of Soberana 02 along with one of Soberana Plus vaccine.

To the mentioned Cuban immunizers are added vaccine candidates Mambisa, also from the CIGB and the only one to be applied by nasal route, which got permission from local health authorities to start phase II of clinical trials; and Soberana 01, from the IFV.